Connect with us

Science

New drug's potentially fatal side effects obscured by 'soothing acronym,' doctors say

Published

on

New drug's potentially fatal side effects obscured by 'soothing acronym,' doctors say

Seventy-nine-year-old Genevieve Lane volunteered to take the Alzheimer’s drug Leqembi in a clinical trial because she was forgetting words and misplacing her keys.

Infusions of the drug gave her headaches so severe they sent her to bed. A week after the third dose, she was at a restaurant with her best friend when her speech slurred and she had a seizure. Five days later she was dead.

An autopsy found that Lane died of a mysterious side effect that has a name that sounds like it might be part of an Italian opera, but has doctors on edge.

The complication called ARIA has nothing to do with music. It is a term adopted by an influential group of pharmaceutical executives and academic scientists to describe potentially fatal bleeding and swelling in the brain caused by drugs like Leqembi.

“Mom believed the drug would help slow progression of her memory problems or do nothing,” said Lane’s daughter, Yvonne Battaglia. “She didn’t know it might kill her.”

Advertisement

Genevieve Lane, 79, of The Villages, Fla., not long before she died in September, 2022. An autopsy blamed Leqembi, a drug for Alzheimer’s disease.

(Lane family)

Lane’s death, and that of two other trial participants, has raised concerns among some doctors, who question whether Leqembi’s risks are worth its benefits, particularly for the population of older adults it was approved for.

Some of these doctors are urging that a new name be given to the drug’s potential side effects to better alert healthcare professionals to its risks.

Advertisement

ARIA is short for “amyloid-related imaging abnormalities,” with imaging referring to the MRI scans needed to find the brain bleeding and swelling.

“Clearly, it is more than just an imaging abnormality,” said Dr. Matthew Schrag, a Vanderbilt University neurologist, who helped with an autopsy that concluded Lane died of brain swelling and bleeding that was likely caused by Leqembi.

“My feeling is that ARIA is too euphemistic of a term. It conveys that this isn’t serious, and it certainly can be,” he said.

Leqembi, known generically as lecanemab, is a monoclonal antibody that works to remove a protein called amyloid from the brain. It received full Food and Drug Administration approval in July.

Eisai, a Japanese drugmaker that has partnered with Biogen, is promoting Leqembi to doctors and people concerned about their memories.

Advertisement

“Get ahead & stay ahead for longer,” an Eisai website says about the drug. It also says that “ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events rarely can occur.”

In a recent article, a Stanford neurologist and his colleagues detailed their concerns about ARIA, which they called a “soothing acronym” for brain bleeding and swelling.

“It does certainly have the ring of something that a pharmaceutical company or public relations person would come up with,” Dr. Michael Greicius said in an interview.

Leqembi is approved for mild dementia and also a diagnosis known as mild cognitive impairment, where patients have more memory problems than others their age but can compensate and continue their daily activities. People with MCI have been found to be at greater risk for developing dementia; but in many cases, their memory problems stay the same or even improve.

The FDA has required that the company warn doctors about ARIA. The agency says the condition, which affected more than 20% of those taking the drug in a large trial, can be managed by requiring patients to get repeated MRI scans to look for bleeding and swelling.

Advertisement

“The FDA maintains that the benefits of Leqembi outweigh its risks when used according to the approved labeling,” said Dr. Teresa Buracchio, director of the FDA’s neuroscience office.

Libby Holman, an Eisai spokesperson, called ARIA “globally established nomenclature.”

Because of the risk of ARIA, some Los Angeles medical centers are taking extra precautions.

At Keck Medicine of USC, a neurologist is available 24/7 to take calls from families of those taking Leqembi, since a headache or sudden confusion can be a sign of ARIA, said Dr. Helena Chui, chair of the neurology department.

At UCLA and Cedars-Sinai Medical Center, warnings pop up in a patient’s electronic health record to ensure that all medical staff know the patient is taking Leqembi, because it can interact with certain other medications to make brain bleeding far worse.

Advertisement

And at all three medical centers it takes more than a single doctor to prescribe the drug. Each patient’s case must be reviewed by a panel of doctors and other staff — similar to how complex cancer cases are evaluated.

“We want to keep safety first,” said Dr. Keith Vossel, UCLA professor of neurology. “This is the most complicated, complex drug that we’ve prescribed in the dementia field.”

Other physicians say they won’t prescribe the drug.

“If there was a medication that worked, I would be the first person to use it,” said Dr. Clifford Sigel, a neurologist in Santa Monica. “But I won’t be using this in my practice.”

He pointed to a large clinical trial of Leqembi that led to its approval. It found that patients who took the drug saw their memory decline 27% more slowly — or less than half a point on an 18-point cognitive scale — than their counterparts who took a placebo. Sigel and other doctors doubt patients or their families would notice the difference.

Advertisement

Eisai’s Holman disputed claims that the drug does not work. She noted that a panel of outside experts convened by the FDA had voted unanimously that trial data confirmed its clinical benefit.

The name ARIA traces to July 2010 when “turmoil ensued” at an international scientific conference that the Alzheimer’s Assn. holds each year, according to an article by two scientists working in the field.

The FDA had proposed that companies testing new anti-amyloid drugs exclude any volunteer from clinical trials who had more than two brain microbleeds, according to an Alzheimer’s Assn. report. The tiny hemorrhages are sometimes found in healthy people and those with Alzheimer’s or other illnesses.

The agency also said it would require any volunteer who experienced a brain microbleed during the clinical trial to cease taking the drug.

The companies and academics working on the trials viewed the new FDA requirements as “excessively restrictive,” said the report by the association, a nonprofit that has become a powerful force in dementia science.

Advertisement

The industry and academic scientists feared the FDA proposal would stall research on the experimental drugs, the report said, and limit their use.

The drug companies asked the association to debate the FDA’s guidance at its Research Roundtable. Pharmaceutical and medical testing companies can become members of the roundtable by paying the association a $50,000 annual fee.

The association said that “one key question” taken up by the roundtable was whether ARIA was a temporary symptom of the new drug — much the way nausea and hair loss are side effects of chemotherapy — or evidence that anti-amyloid medicines may have more serious adverse effects. That question was never settled.

“Current knowledge doesn’t provide definitive answers to this critical question,” the association said in the 2011 report explaining the roundtable’s work.

Despite the unknowns, the roundtable proposed that volunteers be allowed into the trials even if they had as many as four brain microbleeds. The group said volunteers could keep getting the drug infusions if they developed brain bleeding as long as they did not have significant worsening of symptoms such as headaches and confusion.

Advertisement

The roundtable also proposed calling the brain bleeding and swelling ARIA.

The FDA “subsequently revised and updated the original advice…in a manner consistent” with the roundtable’s suggestions, wrote three of its members.

“Scientific evidence at the time led the workgroup to propose excluding people who have four or more microbleeds from clinical trials,” the association told The Times in a statement. “The FDA agreed.”

The association declined to answer questions on whether the name ARIA should be changed.

An FDA official told The Times that the industry group’s advice was just one of the factors the agency considered before it revised its 2010 guidelines.

Advertisement

More than a decade later, little more is known about why ARIA occurs or how to recognize it.

One problem is that a patient with ARIA can look like they’re having a stroke. And when stroke patients are taken to an emergency room, the first treatment doctors often consider is a clot-dissolving medicine called tPA, which can make brain bleeding worse.

That’s what happened to a 65-year-old woman taking Leqembi in a trial who arrived at a Chicago ER with stroke-like symptoms, according to a report published in February 2023. Doctors gave her tPA.

“As soon as they put it in her, it was like her body was on fire,” the woman’s husband said in a news story in the journal Science. “She was screaming, and it took like eight people to hold her down.”

The woman died, and an autopsy showed extensive bleeding in her brain, leading doctors to conclude the combination of the two drugs may have caused her death.

Advertisement

Knowing about that risk, Southern California doctors have been teaching emergency room staff to find out if patients thought to be suffering a stroke may be taking Leqembi.

“We’ve had to train and discuss this with the ER, the neuroradiology team and urgent care,” said Dr. Sarah Kremen, who leads Cedars Sinai’s Alzheimer’s clinical trial program. “You must ask this person, ‘Are you taking this medication?’”

An FDA database that collects reports of adverse drug reactions from doctors and others shows 23 deaths of patients taking Leqembi.

Holman at Eisai said it would be incorrect to assume the deaths were caused by Leqembi. She noted that Alzheimer’s patients have a higher risk of death because of the natural course of the disease.

In the large trial, less than 1% of patients died — the same rate whether they were taking the drug or the placebo.

Advertisement

Buracchio at the FDA said the agency takes “all adverse event reports seriously.” But she said the agency’s evaluation of the reports “must take the treated population into account,” which in this case is typically older or elderly adults.

To teach doctors about ARIA, Eisai created a website called understandingaria.com. It tells doctors that ARIA “usually resolves without intervention or treatment modification.”

In a brochure for healthcare providers, Eisai assures physicians that infusions may continue if an MRI turns up evidence of microbleeds as long as there are four or fewer and that the discomfort doesn’t disrupt the patient’s activities.

For Genevieve Lane, an MRI discovered four brain microbleeds before she started taking Leqembi in the trial.

After Lane died, an autopsy found more than 30 microbleeds in her brain, including some that could not be seen on the MRI, according to a report in Nature Communications.

Advertisement

The report’s authors, who included Schrag at Vanderbilt, questioned whether the pre-treatment limit of four brain microbleeds was stringent enough and called for higher standards.

The FDA told The Times that the agency had reviewed the available data and had not identified a specific number of preexisting microhemorrhages that would make it unsafe for patients to take anti-amyloid drugs like Leqembi.

“However, we will continue to monitor the accruing safety data,” the agency said.

Other doctors have questioned what happens to the memories of those who suffer ARIA, even if the bleeding and swelling appears to resolve.

Dr. Madhav Thambisetty, a senior researcher at the National Institute of Aging, said he was concerned by a report in a French medical journal about two women with mild dementia who experienced serious ARIA during a trial. One suffered severe seizures; 11 months later, her memory score dropped by nine points on a 30-point scale. The other patient developed a brain bleed described as “massive”; she lost a significant part of her vision, and her memory score declined by 12 points on the same scale.

Advertisement

An FDA scientist reviewing reports of patients who suffered high numbers of microbleeds in the clinical trial also noted the possible harm to their cognition in her January 2023 report on Leqembi.

One of the patients that Dr. Deniz Erten-Lyons pointed to was a 68-year-old man who had four microbleeds before starting the infusions. After treatment, he began to lose his vision and was hospitalized because of a seizure. An MRI found 96 microbleeds.

Thambisetty said he and Dr. Rob Howard of University College London wrote to Eisai last year to request information about what happened to the cognition of those who suffered ARIA in trials.

Eisai has not responded to their request, he said.

“I’m concerned about the lack of full and transparent reporting,” Thambisetty said. “It’s really important to know what happens to these patients.”

Advertisement

Holman said the company’s analysis of trial data showed that ARIA did not impact cognition.

“Eisai is transparent,” she said. The company follows guidelines for sharing clinical data established by PhRMA, the industry trade association, Holman said.

Greicius, the Stanford professor, also asked Eisai for trial data that would break down results for each volunteer to better understand ARIA and whether patients benefited as more amyloid was removed from their brains.

The response from Eisai, he said, was, “Thanks for your interest, but we can’t release the data.”

Advertisement
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Science

AI and memory deletion: Inside the medical quest to cure grief

Published

on

AI and memory deletion: Inside the medical quest to cure grief

When Cody Delistraty lost his mother in 2014, he was surprised by the various ways that he, his brother and his father dealt with their grief. The journalist and speechwriter had expected his family’s experiences to be aligned, that there would be a, “homogeneity to grieving.” The differences led Delistraty to wonder whether loss was more complicated than advertised.

In America, grief is often framed as a journey from Point A to Point B, a linear path efficiently chugging through stages like denial and anger, ultimately heading toward acceptance. But anyone who has experienced a loss firsthand understands that it isn’t so simple. Grief can be isolating, confusing and unyielding.

Shelf Help Logo

Shelf Help is a new wellness column where we interview researchers, thinkers and writers about their latest books — all with the aim of learning how to live a more complete life.

Advertisement

In 2022, a new addition to the DSM-5 (“Diagnostic and Statistical Manual of Mental Disorders”) caught Delistraty’s eye: prolonged grief disorder. It’s a rare condition in which grief becomes so severe that it interferes with daily life. The classification opens the door to medical solutions: pharmaceuticals are in early testing stages, and a slew of new digital, psychedelic and other treatments are emerging.

Delistraty’s new book, “The Grief Cure: Looking for the End of Loss,” (Harper) follows his inquisitive sampling of available and future therapies, all while wondering whether grief is a problem that needs to be solved.

Your understanding of grief initially centered on a concept known as the five stages: denial, anger, bargaining, depression and acceptance. How did that shift?

Portrait of Cody Delistraty standing in front of a bookcase

Cody Delistraty (Grace Ann Leadbeater)

When Elisabeth Kübler-Ross came up with the five stages, she was talking to patients who were coming to terms with their own deaths, not with their own grief, which is similar but also very different. There was a study that tracked grievers from various demographics and found that most people actually experience a progression, but my issue with the typical interpretation of the five stages is that it’s presented as the right way to grieve, that there’s a method you can master and that the end game is acceptance.

Advertisement

America has a culture of individuality and mastery — we want to achieve, we want to overcome, we want to bootstrap our way to success. But in grief, we only set ourselves back trying to do this. After a loss is the time to pause and reflect, and even if you do go through these stages to some degree, trying to rush through them or extract value in order to get to acceptance and move on is a fundamentally wrong way of looking at it.

“America has a culture of individuality and mastery — we want to achieve, we want to overcome, we want to bootstrap our way to success. But in grief, we only set ourselves back trying to do this.”

— Cody Delistraty, author of “The Grief Cure.”

Your book confronts the isolation of grieving and how it’s so often considered unseemly or inappropriate when done publicly. Grief is culturally framed as an individual journey, and yet it’s a universal fact of life. What do you think accounts for this disconnect?

Advertisement

This paradigm shift from public to private grieving is a relatively recent phenomenon. Americans, especially, are weary of talking or asking about loss. This is a symptom of “happiness culture,” where grief is considered a burden and you don’t want to seem unhappy or bring others down. The disintegration of local communities exacerbates this. And then this false idea that closure marks a victory over grief. Keeping grief private implies that you did your job. There’s morally valuable willpower. You did it. You got over it.

I think self-care has been the problematic marketing breakthrough of the 21st century, in which the more challenging aspects of being a human, like disappointment, sadness and grief, get pushed out of the frame. They’re not within our consumption narrative, and they’re not within the way we want to present to others.

What surprised me while researching is that it seems like people are actually bubbling with the desire to talk about these things. When I was researching for the book, I got sick of holing up in hotels, so I went to a bar and ended up talking with someone who told me about her recent divorce, which she called the greatest loss of her life. She hadn’t really talked to anybody about it, and it was so nice to connect over loss. When people are open, it can snowball into greater openness.

Our society can place varying value on different types of loss, resulting in some to fall through the cracks, like that woman with her divorce. But grief exists on a spectrum. In the book, you discuss ambiguous loss. Can you tell me more?

Book jacket for "The Grief Cure" by Cody Delistraty

(Courtesy of Harper Collins)

Advertisement

The term ambiguous loss was coined by Pauline Boss at the University of Minnesota, who worked with the families of soldiers who went missing in Vietnam. Boss defined it as “a relational disorder caused by the lack of facts surrounding the loss of a loved one,” but today, it encompasses a wide variety of loss.

Climate grief is a big and very modern one. There was a European study that found a third of respondents are extremely worried about climate change. That’s a huge instance of ambiguous grief because there’s disappearance of species and landscapes, there’s an increase in climate refugees, but you can’t really point to a body in a casket and say this is what I’m grieving.

Relationships are another big example. In the book, I went to breakup boot camp to explore losing a loved one outside of death. Friend breakups can be devastating. I really push against the idea of hierarchies and grief. There isn’t a fundamental ranking within grief, and it is subjective to the relationship you had to that person or thing.

Your experiences brought you to the cutting edge of grief research. What do you make of the future of grief treatments?

When I was writing the AI [artificial intelligence] chapter of re-creating technologically deceased loved ones, it was super cutting-edge and wild. Then, of course, it all hit the news cycle pretty intensely with Chat-GPT. Optogenetics for memory deletion could be something we’re faced with in another decade or two. There will be medical technologies where we can take a lot of the pain and burden out of loss. My book questions whether that’s really for the best. We should be thinking about this now before the time comes.

Advertisement

TAKEAWAYS

from “The Grief Cure”

Psilocybin is a huge scientific breakthrough for grief. I talked to one of the most renowned psilocybin researchers, Robin Carhart-Harris, who told me about this guy, Kirk Rutter, whose mother had died, he’d been in this terrible car accident and then he went through a romantic breakup all in the span of about a year. Carhart-Harris’ team gave him just two pills of synthesized psilocybin, donned him with an eye mask and calm music, and he had this incredible perspective shift. He cycled through memories of his mom and realized he didn’t have to maintain the most painful parts, but he could still hold onto her and respect her memory. That treatment made him look at grief differently.

Advertisement

What is your best advice for somebody really stuck in their grief?

There’s no right way of doing it, but don’t rush it. As awful as this time is, there’s so much to be gleaned from really looking inward, reflecting on yourself and your feelings, and thinking about the person you’ve lost. I rushed after my mom died, trying to push past the pain, and here I am, a decade later, writing a book about it. These things really do take time.

I also recommend telling your people what you need from them. The vast majority of people want to talk about these things, they want to be helpful, but especially in the U.S., we are very bad at knowing what that looks like. To the degree that you can, communicate your needs. I think you’d be surprised by the degree to which people will be there for you.

Should someone in grief be aiming for closure?

I think closure is a mythical idea. Nancy Berns, a professor at Drake University, has done a lot of great work on closure and how it’s a social construct. We too often skip over the grappling-with and reflecting-on of grief in order to get to this mythical place of closure when really the truest value is being able to hold that loss in one part of your life while holding a future-looking part in another.

Advertisement

We see this push for closure reified across American culture. One of the biggest shocks for me was bereavement leave, where the median is only five days according to a 2024 study, and this only applies to a close family death. There’s no U.S. federal law requiring leave. This bolsters the idea that closure is part and parcel of productivity, of getting back to normal, of getting back to work.

Our rituals around grief are one-off. We go to a funeral, and that’s it. You get support for an hour, and then it’s over. We’d do well to really reflect on more personal, creative rituals that have more intimate meaning and can be continued over a longer period. This shift would help people with the understanding of time lines around grief. It all takes so much longer than we think. You miss so much when you rush through to tick the box of closure, and frankly, when you do so, you’re really not grieving at all.

a figure sit in the threshold of a door opening to a void

(Maggie Chiang / For The Times)

Endicott is a writer and multi-disciplinary artist based in Denver. Her work has appeared in a number of publications including the New York Times, Scientific American, the Guardian, Elle, Electric Lit and Bomb Magazine. You can find her on Instagram @weirdbirds.

Shelf Help is a new wellness column where we interview researchers, thinkers and writers about their latest books — all with the aim of learning how to live a more complete life. Want to pitch us? Email alyssa.bereznak@latimes.com.

Advertisement

Continue Reading

Science

L.A. County plans to put $5 million toward wiping out medical debt

Published

on

L.A. County plans to put $5 million toward wiping out medical debt

Los Angeles County is moving forward with a pilot program to relieve medical debt for struggling residents, setting aside $5 million for a planned agreement with a national nonprofit that buys and erases such debts.

County supervisors voted Tuesday to allocate money for a county agreement with Undue Medical Debt to carry out the new program. The effort is expected to launch later this year, focusing on debt stemming from hospital care and targeting L.A. County’s “lowest income residents.”

“No one should be driven into poverty because they got sick,” Supervisor Janice Hahn, who put forward the proposal with Supervisor Holly Mitchell, said in a statement.

“But medical debt remains a huge problem in this country, and it can be devastating for families and their financial well-being. Luckily for us, we have an opportunity to make a difference.”

Advertisement

Hospitals stuck with unpaid bills can bundle and sell the debt at a discount to collection agencies that try to recoup the owed money for profit. Undue Medical Debt instead buys the discounted debt and forgives it. The nonprofit said it can erase an average of $100 in debt for every dollar that is donated.

“Five million dollars can really go a long way,” said its vice president of communications and marketing Daniel Lempert. County officials estimated that amount could eliminate $500 million of debt for 150,000 residents.

Across the country, Undue Medical Debt has partnered with local governments such as Cook County, Ill. and Toledo, Ohio. to fund such efforts. Lempert said that under such agreements, the nonprofit typically reaches out to local hospitals and other health care providers to identify and purchase medical debt affecting financially strapped patients, then gets reimbursed by the local government for the cost of debts affecting their residents.

Under its guidelines for financial hardship, Undue Medical Debt works to relieve debt for people from households making no more than four times the federal poverty level — a calculation equating to $124,800 this year for a family of four — or whose medical debt amounts to 5% or more of their income.

L.A. County is still working out who will be eligible under its pilot program, but its broad goal is to reach “our lowest-income residents and the working poor who have catastrophic amounts of medical debt,” said Dr. Naman Shah, director of the division of medical and dental affairs at L.A. County Public Health.

Advertisement

The L.A. County pilot program will focus specifically on medical debts for hospital care, Shah said. Local residents cannot apply directly for their medical debt to be wiped out, but will be informed if Undue Medical Debt has eliminated some or all of their unpaid debt.

“You’ll get a letter out of the blue saying, ‘X, Y or Z debts have been relieved. You no longer owe them. Keep this as a receipt,’” Lempert said.

In Los Angeles County, public health officials have estimated that medical debt totaled more than $2.9 billion in 2022, burdening 1 in 10 adults in the county — a higher percentage than suffered from asthma, according to the public health department. More than half of those who said they were burdened by medical debt had taken on credit card debt to pay medical bills, its analysis found.

The problem has persisted even as more L.A. County residents gained insurance coverage, underscoring the need for a targeted approach, the public health department said.

County officials estimated earlier this year that wiping out nearly $3 billion in medical debt for L.A. County residents through an intermediary would cost $24 million. Other municipalities have turned to funding from the American Rescue Plan Act for such debt relief, but L.A. County had “fully allocated” that money as of January, according to a staff report.

Advertisement

The public health department said it planned to instead use $5 million in one-time county funding for the pilot program, which it said would roll out in stages, starting with “the most vulnerable residents.” Shah said his hope was to raise enough additional money to not have to set priorities about which struggling residents to help.

A study released earlier this year raised questions about the effectiveness of buying up medical debt: A National Bureau of Economic Research working paper that examined medical debt relief for more than 83,000 people from 2018 to 2020 concluded it had no effect, on average, on financial distress or mental health. The research was done in partnership with Undue Medical Debt, then known as RIP Medical Debt.

Despite the “disappointing results,” the researchers wrote, “there is still potential that medical debt relief targeted further upstream or in different populations could yield meaningful benefits.” Stanford University professor of economics Neale Mahoney said the cheapest debts to buy often date back five years or more.

By that point, “a lot of these folks had a lot of other issues, and relieving one of their issues without helping … all of the other financial issues they had wasn’t enough to move the needle,” he said. One solution is to “move more upstream,” and provide debt relief earlier, “before people are too scarred by the debt collection process.”

Mahoney praised the response of the nonprofit, saying it was “taking the study to heart.” Undue Medical Debt president Allison Sesso said in April that it had already made changes since the period covered by the study, including buying medical debt directly from hospitals before it goes to debt buyers or collection agencies.

Advertisement

Sesso also said her group was “collaborating with local governments across the country to concentrate debt erasure to a specific locality to deepen our impact.”

Focusing such efforts in a targeted area ramps up the chances it may be able to wipe out multiple debts for an individual patient, Lempert said.

Shah added that the study did not show what would happen if debt relief happened alongside other prevention efforts. In L.A. County, “there is a larger agenda on medical debt — of which this is just one part.”

Under a broader plan to combat medical debt in L.A. County, the public health department also wants to gather data on how hospitals collect debt and assist strapped patients, create an online portal to apply for financial help, and expand legal aid services, among other proposed steps.

Public health department director Barbara Ferrer told county supervisors Tuesday that their goal is to stop medical debt “at the source,” before it starts piling up for L.A. County residents.

Advertisement

“We don’t want to be coming back to you in five years trying to pay off medical debt again,” Ferrer said.

Continue Reading

Science

L.A.'s newest dinosaur has its forever name

Published

on

L.A.'s newest dinosaur has its forever name

The people have spoken, and L.A.’s newest Jurassic-era resident has its forever name.

Dinosaur fans who responded to the museum’s request for input overwhelmingly chose to call the Natural History Museum’s new 70-foot-long sauropod “Gnatalie.”

More than 36% of roughly 8,100 participants in a public poll chose that name, which is pronounced “Natalie,” from among five options offered by the museum.

A rendering of the new dinosaur display at the Natural History Museum. Dinosaur fans who responded to a museum poll have decided to call the 70-foot-long sauropod “Gnatalie.”

(Frederick Fisher and Partners, Studio MLA, and Studio Joseph / NHMLAC)

Advertisement

The punny moniker is a reference to the relentless swarm of gnats that plagued paleontologists, students, museum staff and volunteers during the 13-year effort to unearth the dinosaur’s remains from a quarry in southeast Utah. Museum staff nicknamed the dinosaur Gnatalie while they were still digging it up, a process that lasted from 2007 to 2019.

The long-necked, long-tailed skeleton will be the focal point of the NHM Commons, a $75 million welcome center currently under construction on the southwest end of the museum in Exposition Park. Slated to open this fall, the Commons will offer gardens, an outdoor plaza, a 400-seat theater and a glass-walled welcome center that can be toured without a ticket.

“The efforts of hundreds of people contributed to what you see here, ground to mount,” said paleontologist Luis Chiappe, director of the Dinosaur Institute at the Natural History Museum of Los Angeles County.

The specimen appears to be part of a new species, similar to the Diplodocus, which will be scientifically named in the future. Thanks to celadonite minerals that replaced organic matter during the fossilization process, the mounted skeleton has a unique greenish-brown hue.

Advertisement

The skeleton is made up of about 350 fossils from six different animals whose bones washed into a river after death some 150 million years ago and commingled.

“We are delighted to see how many people voted and how much they loved our name for this unusual dinosaur,” said Lori Bettison-Varga, President and Director of the Natural History Museums of Los Angeles County.

Continue Reading

Trending